<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>12966657</identifier>
<setSpec>1405-9940</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Olvera Cruz, Sergio</dc:author>
<dc:description xml:lang="en">Treatment of chronic heart failure still needs to be improved. Blockade of ET-1 and TNF-alpha, as well as the combined inhibition of ACE and NE have demonstrated limited benefits, thus other strategies continue being evaluated. This article reviews current concepts regarding the blockade of arginine vasopressin receptors (AVP) and the selective inhibition of matrix metalloproteinases (MMPs). Results with AVP blockade in humans have been encouraging, whereas inhibitors of MMPs continue under preclinical experimental phases and are controversial.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2003 Apr-Jun </dc:date>
<dc:title xml:lang="es">Nuevas terapéuticas para la insuficiencia cardíaca?</dc:title>
<dc:title xml:lang="en">[New treatments for heart failure?].</dc:title>
<dc:publisher>Archivos de cardiologia de Mexico</dc:publisher>
</metadata>
</record>
</pubmed-document>
